Does Rallies show 13F holders for CABA?

Yes. Rallies tracks hedge fund and 13F ownership data for CABA, including fund names, share counts, latest tracked quarter, and position changes when available.

Is CABA research on Rallies investment advice?

No. Rallies provides research, data, and educational context for CABA. It does not provide personalized investment advice.

CABA (Cabaletta Bio, Inc. Common Stock) Stock Analysis - Hedge Fund Holdings

Cabaletta Bio, Inc. Common Stock (CABA) is a publicly traded Healthcare sector company. As of May 21, 2026, CABA trades at $3.47 with a market cap of $536.45M and a P/E ratio of -1.62. CABA moved +5.20% today. Year to date, CABA is +56.36%; over the trailing twelve months it is +82.98%. Its 52-week range spans $0.99 to $5.46. Analyst consensus is strong buy with an average price target of $13.94. Rallies surfaces CABA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns CABA stock?

Hedge funds tracked by Rallies that own CABA include Redmile Group, Duquesne Family, and Panagora Asset. The latest tracked quarter is Sep 30, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Cabaletta Bio, Inc. Common Stock.

CABA Key Metrics

Key financial metrics for CABA
Metric	Value
Price	$3.47
Market Cap	$536.45M
P/E Ratio	-1.62
EPS	$-2.10
Dividend Yield	0.00%
52-Week High	$5.46
52-Week Low	$0.99
Volume	210
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-167.86M
Gross Margin	0.00%

Top Hedge Funds Holding CABA

Redmile Group holds 442.83K shares of CABA, changed +0.00% as of Sep 30, 2024.
Duquesne Family holds 417.00K shares of CABA, changed +0.00% as of Mar 31, 2024.
Panagora Asset holds 173.52K shares of CABA, changed -45.67% as of Dec 31, 2024.

Latest CABA News

Cabaletta Presents 50% PC-Free Rese-cel Response, Secures 10-Year Supply Deal — May 14, 2026
Cabaletta Bio Prices 51.7M Share Offering at $2.90 to Raise $150M — May 4, 2026
Cabaletta Bio Advances 17-Patient Myositis Trial, 2027 BLA Goal, 1H26 Manufacturing Data — Mar 23, 2026
Jacob Discovery Fund Adds Cabaletta Bio After 26.5% Monthly Surge — Feb 18, 2026
Cabaletta Bio Starts Pivotal Myositis CAR-T Trial, Aims for 2027 BLA with Automated Manufacturing — Feb 13, 2026

Recent CABA Insider Trades

Chang David J. bought 8.80K (~$19.89K) on Jan 21, 2026.
Binder Gwendolyn bought 11.31K (~$24.76K) on Jan 21, 2026.
Tomasello Shawn bought 22.73K (~$50.32K) on Jan 21, 2026.

CABA Analyst Consensus

8 analysts cover CABA: 0 strong buy, 7 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $13.94.

Common questions about CABA

Who owns CABA stock?: Hedge funds tracked by Rallies that own CABA include Redmile Group, Duquesne Family, and Panagora Asset. The latest tracked quarter is Sep 30, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Cabaletta Bio, Inc. Common Stock.
Does Rallies show 13F holders for CABA?: Yes. Rallies tracks hedge fund and 13F ownership data for CABA, including fund names, share counts, latest tracked quarter, and position changes when available.
Is CABA research on Rallies investment advice?: No. Rallies provides research, data, and educational context for CABA. It does not provide personalized investment advice.